(CercleFinance.com) – Johnson & Johnson announced the first results of a Phase 3 study of Tremfya (guselkumab) in the treatment of moderately to severely active ulcerative colitis.
The study showed that 50% of patients receiving 200 mg of Tremfya every four weeks and 45.2% of patients receiving 100 mg every eight weeks achieved clinical remission at week 44, compared to 18.9% for the placebo.
Additionally, 67% and 71% of patients in clinical remission also achieved endoscopic remission.
Both dosages of Tremfya also met all nine key secondary endpoints, with significant improvements compared to placebo.
These results suggest that Tremfya may offer a promising new treatment option for patients with ulcerative colitis.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
